PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34359683-5	2021	We experimentally tested bexarotene as a potential BRF2 inhibitor.	Bexarotene	25-35	BRF2 RNA polymerase III transcription initiation factor subunit	Homo sapiens	51-55	
34359683-6	2021	We found that bexarotene (Bex) treatment resulted in a dramatic decline in oxidative stress and Tert-butylhydroquinone (tBHQ)-induced levels of BRF2 and consequently led to a decrease in the cellular proliferation of cancer cells which may in part be due to the drug pretreatment-induced reduction of ROS generated by the oxidizing agent.	Bexarotene	14-24	BRF2 RNA polymerase III transcription initiation factor subunit	Homo sapiens	144-148	
34359683-6	2021	We found that bexarotene (Bex) treatment resulted in a dramatic decline in oxidative stress and Tert-butylhydroquinone (tBHQ)-induced levels of BRF2 and consequently led to a decrease in the cellular proliferation of cancer cells which may in part be due to the drug pretreatment-induced reduction of ROS generated by the oxidizing agent.	Bexarotene	26-29	BRF2 RNA polymerase III transcription initiation factor subunit	Homo sapiens	144-148	
34359683-7	2021	Our data thus provide the first experimental evidence that BRF2 is a novel player in the DNA damage response pathway and that bexarotene can be used as a potential inhibitor to treat cancers with the specific elevation of oxidative stress.	Bexarotene	126-136	BRF2 RNA polymerase III transcription initiation factor subunit	Homo sapiens	59-63